2022 Study (Parts 3 & 4)

During the 2022 Study, participants will receive the investigative treatment via an oral pill.

There is one screening appointment prior to the inpatient stay and a single follow-up phone call. Compensation for study participation may be provided for time and travel up to $1,550.

This study has been approved by an independent ethics committee.

Call Lindsay at 651-368-3360 or email her at lindsayd@nucleusnetwork.com to discuss your eligibility today!